GBT440

A Study of the Safety, Blood Levels and Biological Effects of GBT440 in Healthy Subjects and Subjects With Sickle Cell Disease

A Study of the Absorption, Metabolism, and Excretion of GBT440 in Healthy Male Subjects

A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects

Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects

Study to Evaluate Effects of Investigational Drug on Oxygenation in Healthy Volunteers Under Hypoxic Conditions

Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment

Single-Dose PK Study of GBT440 in Subjects With Renal Impairment

Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF

Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest

An Extension Study to Further Evaluate the Safety, Tolerability of GBT440 in Patients With Sickle Cell Disease Who Participated in the Study GBT440-001

A Phase 3 Double-blind, Randomized, Placebo-controlled, Multicenter Study of Voxelotor Administered Orally to Patients With Sickle Cell Disease